Disc Medicine, Inc. (NASDAQ:IRON) COO Sells $87,873.80 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 1,610 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $87,873.80. Following the transaction, the chief operating officer now owns 40,555 shares in the company, valued at $2,213,491.90. This represents a 3.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Disc Medicine Stock Down 0.2 %

Shares of NASDAQ:IRON opened at $54.35 on Friday. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The company has a 50 day moving average price of $59.26 and a two-hundred day moving average price of $55.02.

Wall Street Analyst Weigh In

IRON has been the subject of several research reports. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. Scotiabank boosted their price objective on Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday, January 21st. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a report on Tuesday, November 5th. Finally, Stifel Nicolaus boosted their target price on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $88.90.

Institutional Trading of Disc Medicine

Large investors have recently bought and sold shares of the business. FMR LLC grew its holdings in shares of Disc Medicine by 358.7% during the fourth quarter. FMR LLC now owns 1,866,248 shares of the company’s stock worth $118,320,000 after buying an additional 1,459,434 shares in the last quarter. Janus Henderson Group PLC increased its position in Disc Medicine by 62.4% during the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after buying an additional 467,988 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Disc Medicine by 23.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock valued at $88,421,000 after buying an additional 262,690 shares during the period. State Street Corp lifted its position in shares of Disc Medicine by 39.7% in the third quarter. State Street Corp now owns 827,910 shares of the company’s stock valued at $40,683,000 after buying an additional 235,115 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Disc Medicine during the 4th quarter worth approximately $5,579,000. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.